Literature DB >> 18353281

BV-2 stimulation by lactacystin results in a strong inflammatory reaction and apoptotic neuronal death in SH-SY5Y cells.

Seon-Joo Kwon1, Tae-Beom Ahn, Min-Yung Yoon, Beom S Jeon.   

Abstract

Neuroinflammation plays a role in the pathomechanism of many neurodegenerative diseases, including Parkinson disease (PD). Proteasome inhibition has also been known to be involved in the pathology of PD. Recent studies have reported that microglial activation and dopaminergic cell death were observed in in vivo lactacystin-induced models of PD. In the present study, we investigated whether proteasome inhibition had a direct effect on the inflammatory reaction. Lactacystin treatment increased the amount of nitric oxide and tumor necrosis factor alpha (TNF-alpha) in culture media containing murine microglia (BV-2). Neuronal cell death was more pronounced when the culture media containing BV-2 cells (BV-2 conditioned media; BV-2 CM) were harvested and treated with human dopaminergic neurons (SH-SY5Y) than when treated with lactacystin alone. Apoptosis was markedly increased by treatment with BV-2 CM, which could be mitigated by pretreatment with minocycline and N(omega)-nitro-l-arginine methyl ester (L-NAME). These results suggest that proteasome inhibition can directly trigger neuroinflammation, which leads to neuronal death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353281     DOI: 10.1016/j.brainres.2008.02.030

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

2.  Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration.

Authors:  Caroline André; Jason C O'Connor; Keith W Kelley; Jacques Lestage; Robert Dantzer; Nathalie Castanon
Journal:  J Neuroimmunol       Date:  2008-07-23       Impact factor: 3.478

3.  The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.

Authors:  D Jantas; A Roman; J Kuśmierczyk; E Lorenc-Koci; J Konieczny; T Lenda; W Lasoń
Journal:  Neurotox Res       Date:  2013-01-10       Impact factor: 3.911

4.  Type-1 interferons contribute to oxygen glucose deprivation induced neuro-inflammation in BE(2)M17 human neuroblastoma cells.

Authors:  Myles Robert Minter; Moses Zhang; Robert Charles Ates; Juliet Marie Taylor; Peter John Crack
Journal:  J Neuroinflammation       Date:  2014-03-06       Impact factor: 8.322

5.  Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.

Authors:  Jolanta Konieczny; Danuta Jantas; Tomasz Lenda; Helena Domin; Anna Czarnecka; Katarzyna Kuter; Maria Śmiałowska; Władysław Lasoń; Elżbieta Lorenc-Koci
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

Review 6.  The ubiquitin proteasome system in glia and its role in neurodegenerative diseases.

Authors:  Anne H P Jansen; Eric A J Reits; Elly M Hol
Journal:  Front Mol Neurosci       Date:  2014-08-08       Impact factor: 5.639

7.  Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.

Authors:  Sławomir Wójcik; Jan Henryk Spodnik; Jerzy Dziewiątkowski; Edyta Spodnik; Janusz Moryś
Journal:  PLoS One       Date:  2015-10-19       Impact factor: 3.240

8.  Modulation of the ATP-Binding Cassette B1 Transporter by Neuro-Inflammatory Cytokines: Role in the Pathogenesis of Alzheimer's Disease.

Authors:  Fawaz Alasmari; Charles R Ashby; Frank S Hall; Youssef Sari; Amit K Tiwari
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

9.  PapRIV, a BV-2 microglial cell activating quorum sensing peptide.

Authors:  Yorick Janssens; Nathan Debunne; Anton De Spiegeleer; Evelien Wynendaele; Marta Planas; Lidia Feliu; Alessandra Quarta; Christel Claes; Debby Van Dam; Peter Paul De Deyn; Peter Ponsaerts; Matthew Blurton-Jones; Bart De Spiegeleer
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

10.  Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model.

Authors:  Maowen Ba; Guozhao Ma; Chao Ren; Xuwen Sun; Min Kong
Journal:  Oncotarget       Date:  2017-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.